MARKET

RLYB

RLYB

Rallybio Corp
NASDAQ
17.05
+0.43
+2.59%
After Hours: 17.05 0 0.00% 19:30 09/28 EDT
OPEN
16.55
PREV CLOSE
16.62
HIGH
17.05
LOW
16.55
VOLUME
16.07K
TURNOVER
--
52 WEEK HIGH
17.57
52 WEEK LOW
3.670
MARKET CAP
90.58M
P/E (TTM)
2.161
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at RLYB last week (0914-0918)?
Weekly Report · 09/21 10:00
Weekly Report: what happened at RLYB last week (0907-0911)?
Weekly Report · 09/14 10:04
Rallybio CFO Transition Amid Pending Avenzo Therapeutics Merger
TipRanks · 09/09 21:20
Rallybio Announces CFO Jonathan Lieber To Transition To Part-Time Employment Effective September 15, Remaining CFO And Principal Financial Officer; Employment To Terminate Upon Closing Of Avenzo Therapeutics Business Combination
Benzinga · 09/09 20:35
Weekly Report: what happened at RLYB last week (0831-0904)?
Weekly Report · 09/07 09:59
Weekly Report: what happened at RLYB last week (0824-0828)?
Weekly Report · 08/31 10:05
Weekly Report: what happened at RLYB last week (0817-0821)?
Weekly Report · 08/24 10:06
Weekly Report: what happened at RLYB last week (0810-0814)?
Weekly Report · 08/17 10:06
More
About RLYB
Rallybio Corporation is a clinical-stage biotechnology company engaged in developing and commercializing life-transforming therapies for patients with severe and rare diseases. It has a pipeline of product candidates aimed at addressing diseases with unmet medical need in the areas of complement dysregulation and hematology. The Company’s lead program, RLYB116, is a differentiated C5 inhibitor with the potential to treat diseases of complement dysregulation, with an initial focus on immune platelet transfusion refractoriness (PTR) and refractory antiphospholipid syndrome (APS). RLYB116 is a novel, once-weekly, small volume, subcutaneously injected C5 inhibitor designed to meet patient demand for a convenient, self-administered at-home solution. Its pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload. Its RLYB114 is a pegylated C5 inhibitor in development for complement-mediated ophthalmic disorders.

Webull offers Rallybio Corp stock information, including NASDAQ: RLYB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RLYB stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RLYB stock methods without spending real money on the virtual paper trading platform.